文献速递产科母胎医学

母亲外周血表观遗传时钟加速老化与早产

Accelerated epigenetic clock aging in maternal peripheral blood and preterm birth.
PubMed 文献 · Am J Obstet Gynecol · 2023-09-09

前瞻性队列纳入163例单胎高危孕妇,<28周采血测AgeAccelGrim;AgeAccelGrim每增1年,<34周早产校正OR为1.13,≥75百分位者<34周早产校正OR为2.36;作者认为加速生物学老化与早产相关。

要点

  • AgeAccelGrim每增1年,<28周早产校正OR为1.18(95%CI 1.04-1.35)。
  • AgeAccelGrim≥75百分位者<28周早产校正OR为3.89(95%CI 1.61-9.38)。
  • 最高AgeAccelGrim四分位组分娩最早(log-rank P<.001)。

核心结论

  • 在高危孕妇中,加速生物学老化与早产相关,且早产越严重关联幅度越大。
  • 作者认为未来需研究证实这些发现并阐明减缓生物学老化的因素,可能改善出生结局。

研究设计与样本

  • 前瞻性队列研究,纳入单胎妊娠且自发性早产高风险、在三级大学医院分娩的孕妇。
  • 于妊娠<28周采集母血,用Illumina EPIC BeadChip(Illumina, Inc, San Diego, CA)测全基因组CpG甲基化。
  • 用Horvath DNA甲基化年龄在线工具估算AgeAccelGrim及其7个DNA甲基化组分;正值示加速生物学老化,负值示相对受试者年龄的较慢老化。
  • 共163例符合纳入标准;主要结局为<34周早产(任何指征),次要结局为<37周和<28周早产。
  • AgeAccelGrim按连续变量和四分位分析;采用卡方检验、t检验、秩和检验、logistic回归(预先校正母亲年龄、细胞计数、低社会经济地位和采样时孕龄)及Kaplan-Meier生存分析,log-rank检验比较生存函数。

主要发现

  • 48%在<37周分娩,39%在<34周分娩,21%在<28周分娩。
  • 足月分娩者AgeAccelGrim中位数为-0.35年(四分位距-2.24至1.31);<37周早产者为+0.40年(四分位距-1.21至+2.28),<34周早产者为+0.51年(四分位距-1.05至+2.67),<28周早产者为+1.05年(四分位距-0.72至+2.72)。
  • <34周早产者7个表观遗传时钟组分估算DNA甲基化升高,但仅纤溶酶原激活物抑制剂1的DNA甲基化差异有统计学意义。
  • AgeAccelGrim每增1年,<37周、<34周、<28周早产的校正OR分别为1.11(95%CI 1.00-1.24)、1.13(95%CI 1.01-1.26)、1.18(95%CI 1.04-1.35)。
  • AgeAccelGrim≥75百分位者<34周早产校正OR为2.36(95%CI 1.10-5.08),<28周早产校正OR为3.89(95%CI 1.61-9.38);<37周早产校正OR为1.73(95%CI 0.81-3.69),跨无效值。

关键数值与推荐

  • AgeAccelGrim每增1年,<37周早产校正OR为1.11(95%CI 1.00-1.24)。
  • AgeAccelGrim每增1年,<34周早产校正OR为1.13(95%CI 1.01-1.26)。
  • AgeAccelGrim每增1年,<28周早产校正OR为1.18(95%CI 1.04-1.35)。
  • AgeAccelGrim≥75百分位者,<34周早产校正OR为2.36(95%CI 1.10-5.08)。
  • AgeAccelGrim≥75百分位者,<28周早产校正OR为3.89(95%CI 1.61-9.38)。

临床怎么用

  • 原文未据此给出临床推荐。

局限性

  • 作者认为未来需研究证实这些发现并阐明减缓生物学老化的因素。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Epigenetic clocks use CpG DNA methylation to estimate biological age. Acceleration is associated with cancer, heart disease, and shorter life span. Few studies evaluate DNA methylation age and pregnancy outcomes. AgeAccelGrim is a novel epigenetic clock that combines 7 DNA methylation components. OBJECTIVE: This study aimed to determine whether maternal biological aging (via AgeAccelGrim) is associated with early preterm birth. STUDY DESIGN: A prospective cohort of patients with singleton pregnancies and at high risk of spontaneous preterm birth delivering at a tertiary university hospital were included in this study. Genome-wide CpG methylation was measured using the Illumina EPIC BeadChip (Illumina, Inc, San Diego, CA) from maternal blood samples obtained at <28 weeks of gestation. AgeAccelGrim and its 7 DNA methylation components were estimated by the Horvath DNA methylation age online tool. Positive values are associated with accelerated biological aging, whereas negative values are associated with slower biological aging relative to each subject's age. The primary outcome was preterm birth at <34 weeks of gestation (any indication). The secondary outcomes were preterm birth at <37 and <28 weeks of gestation. AgeAccelGrim was analyzed as a continuous variable and in quartiles. Exploratory analyses evaluated each of the 7 DNA methylation components included in the composite AgeAccelGrim. Data were analyzed by chi-square test, t test, rank-sum test, logistic regression (controlling a priori for maternal age, cell counts, low socioeconomic status, and gestational age at the time of sample collection), and Kaplan-Meier survival analyses. The log-rank test was used to test the equality of the survival functions. RESULTS: Overall, 163 patients met the inclusion criteria. Of the patients, 48%, 39%, and 21% delivered at <37, <34, and <28 weeks of gestation, respectively. The median AgeAccelGrim was -0.35 years (interquartile range, -2.24 to 1.31) for those delivering at term. Those delivering preterm had higher AgeAccelGrim values that were inversely proportional to delivery gestational age (preterm birth at <37 weeks of gestation: +0.40 years [interquartile range: -1.21 to +2.28]; preterm birth at <34 weeks of gestation: +0.51 years [interquartile range: -1.05 to +2.67]; preterm birth at <28 weeks of gestation: +1.05 years [interquartile range: -0.72 to +2.72]). Estimated DNA methylation of the 7 epigenetic clock component values was increased among those with preterm birth at <34 weeks of gestation, although the differences were only significant for DNA methylation of plasminogen activation inhibitor 1. In regression models, AgeAcccelGrim was associated with an elevated risk of preterm birth with increasing magnitude for increasing severity of preterm birth. For each 1-year increase in the AgeAccelGrim value (ie, each 1-year increase in biological age compared with chronologic age), the adjusted odds of preterm birth were 11% (adjusted odds ratio, 1.11; 95% confidence interval, 1.00-1.24), 13% (adjusted odds ratio, 1.13; 95% confidence interval, 1.01-1.26), and 18% (adjusted odds ratio, 1.18; 95% confidence interval, 1.04-1.35) higher for preterm birth at <37, <34, and <28 weeks of gestation, respectively. Similarly, individuals with accelerated biological aging (≥75th percentile AgeAccelGrim) had more than double the odds of preterm birth at <34 weeks of gestation (adjusted odds ratio, 2.36; 95% confidence interval, 1.10-5.08) and more than triple the odds of preterm birth at <28 weeks of gestation (adjusted odds ratio, 3.89; 95% confidence interval, 1.61-9.38). The adjusted odds ratio for preterm birth at <37 weeks of gestation was 1.73 but spanned the null (adjusted odds ratio, 1.73; 95% confidence interval, 0.81-3.69). In Kaplan-Meier survival analyses, those in the highest AgeAccelGrim quartile delivered the earliest (log-rank P value of <.001). CONCLUSION: Accelerated biological aging was associated with preterm birth among high-risk patients. Future research confirming these findings and elucidating factors that slow biological aging may improve birth outcomes.

来源:Am J Obstet Gynecol,查看原文。版权归原作者所有。

引用

  1. Gascoigne EL, Roell KR, Eaves LA, et al. Accelerated epigenetic clock aging in maternal peripheral blood and preterm birth. Am J Obstet Gynecol. 2023. PMID: 37690595. doi:10.1016/j.ajog.2023.09.003

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。